Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

The stock's rise snapped a five-day losing streak.

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...

Seasoned advisory group including RNA, translation and commercialisation luminaries.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The diagnosed prevalent cases of HIV are projected to increase globally at an annual growth rate of 0.90 pc from 2.00 million ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...